Protection at the Gate

Leyden Labs is fundamentally changing how we protect people from airborne viruses by building a new class of Mucosal Protection Products designed to protect at the site of respiratory infection—the airway mucosa.

Our goal is unprecedented protection, right in the palm of the hand, for those who need it most.

Our nasal sprays are designed to provide unmatched breadth of protection in the airway and overcome major limitations of vaccine-based protection. The premise of our novel intranasal approach has been robustly supported by preclinical studies. As a result, two complementary lead programs have now advanced into clinical development.

Created with BioRender.com

Our approach

Leyden Labs is built on a simple premise: To stop respiratory viral infections, we need to protect at the gate where viruses invade the body.

Delivery of Mucosal Protection Products to the airway is made possible by our world-class molecules, expertise in formulation science, and targeted airway delivery capabilities.

Discover how our scientific approach can redefine protection.

OUR APPROACH →

Love Hugs

News

R&D Updates

September 9, 2026

Leyden Labs Reports Positive Phase 1 Results for RIG-101, Supporting Advancement into Phase 2 to Protect Asthma Patients

Business

June 26, 2026

Globally Recognized Impact Investors Back Leyden Labs’ Mission to Transform Protection Against Respiratory Viruses with €40 Million Investment

R&D Updates

February 4, 2026

Leyden Labs Demonstrates Feasibility of Novel Antibody-Based Nasal Spray for Flu Prevention

Love Sports

About us

Leyden Labs is a clinical-stage biotechnology company that is fundamentally changing how we protect people from airborne viruses. The goal is to provide unprecedented protection, right in the palm of the hand, for those who need it most. We are bringing this vision to life through the collective strength of an experienced team with the expertise and determination to deliver lasting results.

READ MORE ABOUT OUR JOURNEY AND TEAM →

Our investors

We are working together with a strong syndicate of investors and ambassadors. Our VC investors are GV (formerly Google Ventures), Casdin Capital, F-Prime Capital, ClavystBio (a life sciences venture investor established by Temasek), Polaris Partners, Qiming Venture Partners, Invus, Softbank Vision Fund 2, Byers Capital / Brook Byers, Bluebird Ventures, European Innovation Council Fund, Invest-NL and the Gates Foundation. In addition, Leyden Labs has funding support from the European Investment Bank.

To schedule an institutional investor meeting with Leyden Labs, please contact investor.relations@leydenlabs.com.